Source: International Congress 2017 – Cystic fibrosis: treatments and monitoring
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
A. Faniyi (BELFAST, United Kingdom). Predicting the outcome of respiratory Pseudomonas aeruginosa infection in vivo. 1836

Member's Comments

No comment yet.

Related content which might interest you: The independent contribution of Pseudomonas aeruginosa infection to long-term clinical outcomes in bronchiectasis Source: Eur Respir J, 51 (2) 1701953; 10.1183/13993003.01953-2017 Year: 2018 Does a single Pseudomonas aeruginosa isolation predict COPD mortality? Source: Eur Respir J 2014; 44: 794-797 Year: 2014 Persistence and genetic adaptation of Pseudomonas aeruginosa in patients with COPD. Source: Virtual Congress 2020 – Airway infection: the microbiome and beyond Year: 2020 Effects of direct lung dosing of Tobramycin in a rat chronic infection model using Pseudomonas aeruginosa RP73 Source: International Congress 2018 – Mechanisms of respiratory infection Year: 2018 Respiratory commensal streptococcus spp do not modulate the outcome of pseudomonas aeruginosa infection in vivo Source: International Congress 2016 – Cystic fibrosis: various aspects Year: 2016 The clinical evaluation of patients with Pseudomonas aeruginosa detected in respiratory specimens Source: Annual Congress 2012 - Management of pneumonia due to hospital pathogens Year: 2012 Can LCI predict new Pseudomonas aeruginosa colonization among CF patients?> Source: International Congress 2017 – What is the future for paediatric respiratory physiology and sleep? Year: 2017 Comparison between two protocols of preventing treatment of chronic Pseudomonas aeruginosa (Pa) infection Source: Eur Respir J 2005; 26: Suppl. 49, 620s Year: 2005 Novel swine ARDS model induced by Pseudomonas aeruginosa pneumonia and VILI Source: Virtual Congress 2020 – Experimental and laboratory studies in intensive care unit medicine Year: 2020 Pulmonary infections with pseudomonas aeruginosa Source: Eur Respir J 2004; 24: Suppl. 48, 642s Year: 2004 Dental units as infection sources of Pseudomonas aeruginosa Source: Eur Respir J 2008; 32: 1122-1123 Year: 2008 Risk factors and outcomes of pneumonia caused by multidrug-resistant Pseudomonas aeruginosa: a clinical case-control study Source: International Congress 2017 – Respiratory infections in critically ill and immuno-depressed patientes Year: 2017 Experimental Pseudomonas aeruginosa pneumonia: evaluation of the associated inflammatory response Source: Eur Respir J 2007; 30: 1167-1172 Year: 2007 Inhaled phage therapy for the treatment of acute Pseudomonas aeruginosa lung infections Source: International Congress 2018 – Mechanisms of respiratory infection Year: 2018 Antibiotic efficacy varies based on the infection model and treatment regimen for Pseudomonas aeruginosa Source: Eur Respir J, 55 (3) 1802456; 10.1183/13993003.02456-2018 Year: 2020 The effect of erythromycin on the chronic lower airway infection by pseudomonas aeruginosa Source: Eur Respir J 2004; 24: Suppl. 48, 640s Year: 2004 Long term treatment with azithromycin in chronic respiratory infections with pseudomonas aeruginosa Source: Eur Respir J 2006; 28: Suppl. 50, 558s Year: 2006 Significance of positive Stenotrophomonas maltophilia culture in acute respiratory tract infection Source: Eur Respir J 2005; 25: 911-914 Year: 2005 Does Pseudomonas aeruginosa infection alter sputum viscoelastic properties in bronchiectasis patients? Source: International Congress 2018 – Chronic respiratory disease: respiratory muscle function, breathing exercises and airway clearance techniques Year: 2018